Biovica International AB Sustainability Reports
Biovica International AB develops and commercializes blood-based biomarker assays and diagnostic tests, such as DiviTum TKa, to monitor and evaluate the efficacy of cancer treatments.
Sector: Manufacturing
Country: Sweden
Exchange: Nasdaq Stockholm
LEI: 549300VADE1VRR555N78
FIGI: BBG00GBNTM38
19 reports from 2017 to 2026
